I cannot comment in detail on what other countries do.
I can advise, of course, that in some of the countries you noted—in some of those markets—they are the countries producing the vaccines. Through their initial investments, they have perhaps a different pricing regime than we see in straight APAs with other countries. This is in terms of guarding that commercially sensitive information, which is done in discussions with the vaccine suppliers.